Solutions
keyboard_arrow_downServices
keyboard_arrow_downSupport & Resources
keyboard_arrow_downCompany
keyboard_arrow_downContact
One of the UK's first commercial partners of Olink® Proximity Extension Assay (PEA) technology, a sensitive and high-throughput technology. In PEA, pairs of oligonucleotide-labelled antibodies are used to capture and detect target proteins, and the proximity of the antibodies leads to the formation of a DNA amplicon that can be quantified by qPCR or Next Generation Sequencing (NGS).
Considered as a next-gen proteomics platform, Olink® technology is widely recognised and extensively cited in various research fields for protein profiling and biomarker developmen
Supported Olink® Platforms
Proteomics are critical for understanding disease pathology and accelerating protein biomarker discovery.
Our portfolio includes high throughput protein analysis using cutting-edge Olink® technology, a significant leap forward in next generation, disruptive proteomics with proven specificity. We are experts in generating high-quality data using all Olink® proteomic platforms.
Allow the Randox team to assist you in discovering how this versatile assay can advance your research by getting in touch.
Olink® Explore HT
Proteins (per panel): 5,400 + with proven specificity of 99.5% negligible cross-reactivity
Sample: 2 µL
Multiplex Panels: 1
Quantification: Relative with NGS automated workflow readout
Olink® Explore 384
Proteins (per panel) ~3000 high-multiplex biomarker discover with uncompromised data quality
Sample: 1 µL
Multiplex Panels: 8
Quantification: Relative
Olink® Target 96
Proteins (per panel) ~ 1100 covering 15 panels for biological processes and disease areas
Sample: 1 µL
Multiplex Panels: 15 with 92 proteins per panel
Quantification: Relative
Olink® Target 48 Cytokine
Proteins (panels): Each panel contains up to 45 immune-related proteins. These two panels can be combined and processed simultaneously.
Sample: 1 µL
Multiplex Panels: 1
Quantification: Relative
Olink® Flex
Proteins (per panel) ~200 within the complete protein library. Each panel contains between 15-21 proteins.
Sample: 1 µL
Multiplex Panels: Mix & Match with combinability of 99% compared to industry-leading standards.
Quantification: Relative or absolute
Olink® Focus
Proteins (per panel) 5400+ with proven specificity. Custom panels with up to 21 proteins for actionable clinical breakthroughs, designed to empower biomarker utility.
Sample: 1 µL
Multiplex Panels: Custom
Quantification: Relative or absolute
Features and Benefits
Covers all major biological pathways with ~5400 + validated protein assays
High sample throughput for large scale proteomic studies and research
Minimal sample volume with just 60uL for the complete library
Exceptional specificity in comparison to mass spec utilising PEA technology
Compatible with a wide variety of sample types
OLINK® Workflow
Extraction of genomic DNA and sample QC
Sample dilution using the Mosquito® LV
Incubation with PEA Probes
Application of PEA Probes
Next generation sequencing
Data analysis and report
Randox Successfully Completed Olink® Concordance Testing
Randox successfully completed the Explore Concordance challenge as beta testers of the Concordance program, certifying the ability to operate the PEA with the same level of competency as the Olink® Analysis Service.
| Randox Summary Report | Acceptance Criteria | Result | |
|---|---|---|---|
| Randox Summary Report: QC Warnings | 0% | Acceptance Criteria: Max 16% allowed | Result: Passed the QC warning criteria |
| Randox Summary Report: Detectability | 97.2% | Acceptance Criteria: Min 85% allowed | Result: Passed the detectability criteria |
| Randox Summary Report: Intra CV | 9% | Acceptance Criteria: Max 15% allowed | Result: Passed the CV criteria |
| Randox Summary Report: Median correlation coefficient (r) | 0.98 | Acceptance Criteria: Min 0.9 allowed | Result: Passed the correlation criteria. |
| Randox Summary Report: Coefficient of determination (R2) | 0.96 | Acceptance Criteria: Min 0.9 allowed | Result: Passed the correlation criteria. |
Overall, Randox passed all QC criteria, successfully passing the Olink Concordance Test on Explore 3072.
Download Full Report download
Get in touch to discover more
To find out more about our OLink, Biomarker Discovery, enquire now.